Theralase Technologies Inc. V.TLT

Audience survey of uro-oncologists

[DJDawg]

At a meeting recentlly. Options were the FDA approved drugs. Survey hints at the uphill for anktiva and adstiladrin.

[DJDawg]

I'm posting this comment as part of an old post so that the photo gets reposted. Recall that the audience survey for the competitors was not great back in the spring. This was to audience of uro-oncologists. Anktiva + BGG combo was approved end April of this year. The company said that at the time of approval that they had 20,000 doses ready to go. In June, they reported "ANKTIVA®

[CancerSlayer]

Agree...So, well over $1/2 million (per discounted pricing) for only "a single treatment course" (= many individual treatments) when using Anktiva.  The high number of doses & high cost will certainly be a stumbling block for sales & patient compliance, which in turn will likely impact provider usage/prederence imo...not to mention ongoing shortages in locally produced BCG

[DeathXray33]

Looks like Stanley's got Slick-Con on a leash. Poor thing, doesn't know what's coming for it. --------------------------- "Rutherrin and Metformin are both scientifically proven to cross the blood-brain barrier, as well as tumour-specific blood barriers, this new discovery potentially allows the precise targeting of cancer cells by Rutherrin anywhere inside the body, including the